| フォーム4 |
アメリカ合衆国証券取引委員会 ワシントンDC20549 有利益所有権変動報告書 証券取引法第16条(a)、または投資会社法第30(h)条に基づく提出 または、1940年投資会社法の30(h)条 |
|
|||||||||||||||
| 参照 Instruction 1(b)。注：このフォームのコピーを3つ提出し、1つに手動で署名する必要があります。場所が不十分な場合は、 Instruction 1(b)を参照してください。 | |||||||||||||||||
| 発行者の株式の購入または売却の契約、指示、または書面に基づいて取引が行われたことを示すためにこのボックスをチェックすることができます。これは Rule 10b5-1(c) の積極的なディフェンス条件を満たすために意図されています。インストラクション10を参照してください。 | |||||||||||||||||
1. 報告者の氏名と住所*
（ストリート）
|
2. 発行会社名 」「Crime Cam 24/7」 シンボル ジャナックス・セラピューティクス社 [ JANX ] |
5. 報告者と発行会社との関係 （該当するものをすべてチェック）
|
||||||||||||||||||||||||
|
3. 最も早い取引日 (月/日/年) 09/26/2024 | ||||||||||||||||||||||||||
|
4. 訂正の場合、最初に提出された書類の提出日 (月/日/年) |
6. 個人的または共同/グループ申告 (該当するものにチェックマークを付けて下さい)
|
| 表I-獲得、処分、または有益な所有権を持つ非派生証券 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. 証券の名称（説明書3） | 2. 取引日 (月/日/年) | 2A. 実行日（ある場合） (月/日/年) | 3. 取引コード（説明書 8） | 4. 取得した証券（A）または処分した証券（D）（説明書 3、4、および5） | 5. 報告された取引の後に有益に所有している証券数量（説明書 3 および 4） | 6. 所有形式：直接（D）または間接（I）（説明書 4） | 7. 間接的な有益所有権の性質（説明書 4） | |||
| コード | V | 数量 | (A)または(D) | 価格 | ||||||
| 普通株式 | 09/26/2024 | S | 49,497 | D | $46.78(1) | 2,909,678 | D(2) | |||
| 普通株式 | 09/26/2024 | S | 9,592 | D | $46.78(1) | 563,635 | I | Avalon BioVentures I、LPによって(3) | ||
| 普通株式 | 09/26/2024 | S | 50,539 | D | $46.78(1) | 2,970,875 | I | Avalon BioVentures SPV I, L.P.によるもの(4) | ||
| 普通株式 | 09/26/2024 | S | 40,803 | D | $47.77(5) | 2,868,875 | D(2) | |||
| 普通株式 | 09/26/2024 | S | 7,908 | D | $47.77(5) | 555,727 | I | Avalon BioVentures I, LPによるもの(3) | ||
| 普通株式 | 09/26/2024 | S | 41,661 | D | $47.77(5) | 2,929,214 | I | Avalon BioVentures SPV I, LPによるもの(4) | ||
| 普通株式 | 09/27/2024 | S | 45,894 | D | $46.42(6) | 2,822,981 | D(2) | |||
| 普通株式 | 09/27/2024 | S | 8,894 | D | $46.42(6) | 546,833 | I | アバロン・バイオベンチャーズI、LPによる(3) | ||
| 普通株式 | 09/27/2024 | S | 46,861 | D | $46.42(6) | 2,882,353 | I | アバロン・バイオベンチャーズSPV I、LPによる(4) | ||
| 普通株式 | 09/27/2024 | S | 1,511 | D | $47.74(7) | 2,821,470 | D(2) | |||
| 普通株式 | 09/27/2024 | S | 293 | D | $47.74(7) | 546,540 | I | アバロン・バイオベンチャーズI、LPによる(3) | ||
| 普通株式 | 09/27/2024 | S | 1,542 | D | $47.74(7) | 2,880,811 | I | アバロン・バイオベンチャーズSPV I、L.P.による(4) | ||
| 普通株式 | 09/27/2024 | M | 828 | A | $17 | 7,828 | D(8) | |||
| 普通株式 | 09/27/2024 | M | 345 | A | $10.73 | 8,173 | D(8) | |||
| 普通株式 | 09/27/2024 | M | 345 | A | $13.22 | 8,518 | D(8) | |||
| 普通株式 | 09/27/2024 | M | 234 | A | $39.8 | 8,752 | D(8) | |||
| 普通株式 | 09/27/2024 | S | 1,826 | D | $46.19(9) | 6,926 | D(8) | |||
| 普通株式 | 09/30/2024 | M | 434 | A | $17 | 7,360 | D(8) | |||
| 普通株式 | 09/30/2024 | M | 181 | A | $10.73 | 7,541 | D(8) | |||
| 普通株式 | 09/30/2024 | M | 181 | A | $13.22 | 7,722 | D(8) | |||
| 普通株式 | 09/30/2024 | M | 123 | A | $39.8 | 7,845 | D(8) | |||
| 普通株式 | 09/30/2024 | S | 958 | D | $46.24(10) | 6,887 | D(8) | |||
|
表II-取得、処分、または受益所有のデリバティブ証券 (プット、コール、ワラント、オプション、転換証券など) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1。デリバティブ証券のタイトル（Instr. 3) | 2。デリバティブ証券の転換価格または行使価格 | 3。取引日 (月/日/年) | 3A。みなし執行日（もしあれば） (月/日/年) | 4。トランザクションコード（Instr. 8) | 5。 取得（A）または処分された（D）デリバティブ証券の数（Instr. 3、4、5） | 6。行使可能な日付と有効期限 (月/日/年) | 7。デリバティブ証券の基礎となる有価証券のタイトルと金額（Instr. (3 と 4) | 8。デリバティブ証券の価格（Instr. 5) | 9。 取引が報告された後に受益的に所有されたデリバティブ証券の数（Instr. 4) | 10。所有形態：直接（D）または間接（I）（Instr. 4) | 11。間接的な受益所有権の性質（Instr. 4) | ||||
| コード | V | (A) | (D) | 行使可能な日付 | 有効期限 | タイトル | 株式の金額または数 | ||||||||
| ストックオプション (購入権) | $17 | 09/27/2024 | M | 828 | (11) | 07/19/2027 | 普通株式 | 828 | $0 | 28,178 | D(8) | ||||
| ストックオプション (購入権) | $10.73 | 09/27/2024 | M | 345 | (11) | 07/19/2027 | 普通株式 | 345 | $0 | 11,741 | D(8) | ||||
| ストックオプション (購入権) | $13.22 | 09/27/2024 | M | 345 | (11) | 07/19/2027 | 普通株式 | 345 | $0 | 11,741 | D(8) | ||||
| ストックオプション (購入権) | $39.8 | 09/27/2024 | M | 234 | (11) | 07/19/2027 | 普通株式 | 234 | $0 | 7,839 | D(8) | ||||
| ストックオプション (購入権) | $17 | 09/30/2024 | M | 434 | (11) | 07/19/2027 | 普通株式 | 434 | $0 | 27,744 | D(8) | ||||
| ストックオプション (購入権) | $10.73 | 09/30/2024 | M | 181 | (11) | 07/19/2027 | 普通株式 | 181 | $0 | 11,560 | D(8) | ||||
| ストックオプション (購入権) | $13.22 | 09/30/2024 | M | 181 | (11) | 07/19/2027 | 普通株式 | 181 | $0 | 11,560 | D(8) | ||||
| ストックオプション (購入権) | $39.8 | 09/30/2024 | M | 123 | (11) | 07/19/2027 | 普通株式 | 123 | $0 | 7,716 | D(8) | ||||
1. 報告者の氏名と住所*
（ストリート）
発行者に対する報告者（s）の関係
| ||||||||||||||||||||||||
1. 報告者の氏名と住所*
（ストリート）
発行者に対する報告者（s）の関係
| ||||||||||||||||||||||||
1. 報告者の氏名と住所*
（ストリート）
発行者に対する報告者（s）の関係
| ||||||||||||||||||||||||
1. 報告者の氏名と住所*
（ストリート）
発行者に対する報告者（s）の関係
|
| Explanation of Responses: |
| 1. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.49 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| 2. The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| 3. The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| 4. The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| 5. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.50 to $48.14 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| 6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $47.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.28 to $47.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 8. The securities are directly held by Mr. Lichter. |
| 9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.11 to $46.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.24 to $46.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 11. Immediately exercisable. |
| Avalon Ventures XI, L.P., By: Avalon Ventures XI GP, LLC, its general partner, By /s/ Jay B. Lichter, Authorized Signatory | 09/30/2024 | |
| Avalon BioVentures I, LP, By: Avalon BioVentures GP, LLC, its general partner, By /s/ Jay B. Lichter, Authorized Signatory | 09/30/2024 | |
| Avalon BioVentures SPV I, LP, By: ABV SPV I GP, LLC, its general partner, By /s/ Jay B. Lichter, Authorized Signatory | 09/30/2024 | |
| /s/ Jay B. Lichter | 09/30/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||